Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer.

Suwan K, Yata T, Waramit S, Przystal JM, Stoneham CA, Bentayebi K, Asavarut P, Chongchai A, Pothachareon P, Lee KY, Topanurak S, Smith TL, Gelovani JG, Sidman RL, Pasqualini R, Arap W, Hajitou A.

Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18571-18577. doi: 10.1073/pnas.1906653116. Epub 2019 Aug 2.

2.

Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.

Przystal JM, Waramit S, Pranjol MZI, Yan W, Chu G, Chongchai A, Samarth G, Olaciregui NG, Tabatabai G, Carcaboso AM, Aboagye EO, Suwan K, Hajitou A.

EMBO Mol Med. 2019 Apr;11(4). pii: e8492. doi: 10.15252/emmm.201708492.

3.

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.

Przystal JM, Hajji N, Khozoie C, Renziehausen A, Zeng Q, Abaitua F, Hajitou A, Suwan K, Want E, Bomalaski J, Szlosarek P, O'Neill K, Crook T, Syed N.

Cell Death Dis. 2018 Dec 13;9(12):1192. doi: 10.1038/s41419-018-1195-4.

4.

Thermoresponsive Bacteriophage Nanocarrier as a Gene Delivery Vector Targeted to the Gastrointestinal Tract.

Namdee K, Khongkow M, Boonrungsiman S, Nittayasut N, Asavarut P, Temisak S, Saengkrit N, Puttipipatkhachorn S, Hajitou A, Ruxrungtham K, Yata T.

Mol Ther Nucleic Acids. 2018 Sep 7;12:33-44. doi: 10.1016/j.omtn.2018.04.012. Epub 2018 May 1.

5.

Selective Inhibition of Histone Deacetylation in Melanoma Increases Targeted Gene Delivery by a Bacteriophage Viral Vector.

Campbell S, Suwan K, Waramit S, Aboagye EO, Hajitou A.

Cancers (Basel). 2018 Apr 21;10(4). pii: E125. doi: 10.3390/cancers10040125.

6.

Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.

Chira S, Gulei D, Hajitou A, Berindan-Neagoe I.

Trends Biotechnol. 2018 Jul;36(7):653-660. doi: 10.1016/j.tibtech.2018.01.014. Epub 2018 Feb 22.

7.

CRISPR/Cas9: Transcending the Reality of Genome Editing.

Chira S, Gulei D, Hajitou A, Zimta AA, Cordelier P, Berindan-Neagoe I.

Mol Ther Nucleic Acids. 2017 Jun 16;7:211-222. doi: 10.1016/j.omtn.2017.04.001. Epub 2017 Apr 8. Review.

8.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12780-12785. doi: 10.1073/pnas.1615288113. Epub 2016 Oct 24.

9.

The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction.

Tsafa E, Al-Bahrani M, Bentayebi K, Przystal J, Suwan K, Hajitou A.

Oncotarget. 2016 Aug 9;7(32):52135-52149. doi: 10.18632/oncotarget.10662.

10.

Bacteriophage Mediates Efficient Gene Transfer in Combination with Conventional Transfection Reagents.

Donnelly A, Yata T, Bentayebi K, Suwan K, Hajitou A.

Viruses. 2015 Dec 8;7(12):6476-89. doi: 10.3390/v7122951.

11.

Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors.

Yata T, Lee EL, Suwan K, Syed N, Asavarut P, Hajitou A.

Mol Cancer. 2015 Jun 3;14:110. doi: 10.1186/s12943-015-0383-4.

12.

Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.

Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W.

Cancer. 2015 Jul 15;121(14):2411-21. doi: 10.1002/cncr.29344. Epub 2015 Apr 1.

13.

Bacteriophage-derived vectors for targeted cancer gene therapy.

Pranjol MZ, Hajitou A.

Viruses. 2015 Jan 19;7(1):268-84. doi: 10.3390/v7010268. Review.

14.

Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma.

Asavarut P, O'Neill K, Syed N, Hajitou A.

Ther Deliv. 2014;5(9):975-90. doi: 10.4155/tde.14.58. Review.

PMID:
25375341
15.

Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery.

Yata T, Lee KY, Dharakul T, Songsivilai S, Bismarck A, Mintz PJ, Hajitou A.

Mol Ther Nucleic Acids. 2014 Aug 12;3:e185. doi: 10.1038/mtna.2014.37.

16.
17.

Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.

Kia A, Przystal JM, Nianiaris N, Mazarakis ND, Mintz PJ, Hajitou A.

Mol Cancer Ther. 2012 Dec;11(12):2566-77. doi: 10.1158/1535-7163.MCT-12-0587. Epub 2012 Oct 10.

18.

Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.

Przystal JM, Umukoro E, Stoneham CA, Yata T, O'Neill K, Syed N, Hajitou A.

Mol Oncol. 2013 Feb;7(1):55-66. doi: 10.1016/j.molonc.2012.08.001. Epub 2012 Aug 21.

19.

Clathrin-mediated endocytosis and subsequent endo-lysosomal trafficking of adeno-associated virus/phage.

Stoneham CA, Hollinshead M, Hajitou A.

J Biol Chem. 2012 Oct 19;287(43):35849-59. doi: 10.1074/jbc.M112.369389. Epub 2012 Aug 22.

20.

A perspective on non-catalytic Src homology (SH) adaptor signalling proteins.

Reebye V, Frilling A, Hajitou A, Nicholls JP, Habib NA, Mintz PJ.

Cell Signal. 2012 Feb;24(2):388-92. doi: 10.1016/j.cellsig.2011.10.003. Epub 2011 Oct 14. Review.

PMID:
22024281
21.

Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector.

Hajitou A.

Adv Genet. 2010;69:65-82. doi: 10.1016/S0065-2660(10)69008-6. Review.

PMID:
20807602
22.

Interaction between AR signalling and CRKL bypasses casodex inhibition in prostate cancer.

Reebye V, Bevan CL, Nohadani M, Hajitou A, Habib NA, Mintz PJ.

Cell Signal. 2010 Dec;22(12):1874-81. doi: 10.1016/j.cellsig.2010.07.015. Epub 2010 Aug 2.

PMID:
20688158
23.

Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase.

Mitchell J, Paul P, Chen HJ, Morris A, Payling M, Falchi M, Habgood J, Panoutsou S, Winkler S, Tisato V, Hajitou A, Smith B, Vance C, Shaw C, Mazarakis ND, de Belleroche J.

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7556-61. doi: 10.1073/pnas.0914128107. Epub 2010 Apr 5.

24.

A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer.

Trepel M, Stoneham CA, Eleftherohorinou H, Mazarakis ND, Pasqualini R, Arap W, Hajitou A.

Mol Cancer Ther. 2009 Aug;8(8):2383-91. doi: 10.1158/1535-7163.MCT-09-0110. Epub 2009 Aug 11.

25.

Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.

Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK.

PLoS One. 2009;4(3):e4972. doi: 10.1371/journal.pone.0004972. Epub 2009 Mar 30.

26.

An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment.

Mintz PJ, Cardó-Vila M, Ozawa MG, Hajitou A, Rangel R, Guzman-Rojas L, Christianson DR, Arap MA, Giordano RJ, Souza GR, Easley J, Salameh A, Oliviero S, Brentani RR, Koivunen E, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2182-7. doi: 10.1073/pnas.0807543105. Epub 2009 Jan 23.

27.

Tumor vasculature-targeted delivery of tumor necrosis factor-alpha.

Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, Libutti SK.

Cancer. 2009 Jan 1;115(1):128-39. doi: 10.1002/cncr.24001.

28.

A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging.

Hajitou A, Lev DC, Hannay JA, Korchin B, Staquicini FI, Soghomonyan S, Alauddin MM, Benjamin RS, Pollock RE, Gelovani JG, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4471-6. doi: 10.1073/pnas.0712184105. Epub 2008 Mar 12.

29.

Design and construction of targeted AAVP vectors for mammalian cell transduction.

Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, Alauddin MM, Pasqualini R, Arap W.

Nat Protoc. 2007;2(3):523-31.

PMID:
17406616
30.

Molecular PET imaging of HSV1-tk reporter gene expression using [18F]FEAU.

Soghomonyan S, Hajitou A, Rangel R, Trepel M, Pasqualini R, Arap W, Gelovani JG, Alauddin MM.

Nat Protoc. 2007;2(2):416-23.

PMID:
17406603
31.

In vivo detection of gold-imidazole self-assembly complexes: NIR-SERS signal reporters.

Souza GR, Levin CS, Hajitou A, Pasqualini R, Arap W, Miller JH.

Anal Chem. 2006 Sep 1;78(17):6232-7.

PMID:
16944906
32.

A hybrid vector for ligand-directed tumor targeting and molecular imaging.

Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC 3rd, Restel BH, Ozawa MG, Moya CA, Rangel R, Sun Y, Zaoui K, Schmidt M, von Kalle C, Weitzman MD, Gelovani JG, Pasqualini R, Arap W.

Cell. 2006 Apr 21;125(2):385-98.

33.

Vascular targeting: recent advances and therapeutic perspectives.

Hajitou A, Pasqualini R, Arap W.

Trends Cardiovasc Med. 2006 Apr;16(3):80-8. Review.

PMID:
16546688
34.

Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands.

Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W, Pasqualini R.

Cancer Cell. 2004 Sep;6(3):275-84.

35.

Aminopeptidase A is a functional target in angiogenic blood vessels.

Marchiò S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, Hajitou A, Ozawa MG, Trepel M, Giordano RJ, Nanus DM, Dijkman HB, Oosterwijk E, Sidman RL, Cooper MD, Bussolino F, Pasqualini R, Arap W.

Cancer Cell. 2004 Feb;5(2):151-62.

36.

Model of unidirectional transluminal gene transfer.

Arap MA, Lahdenranta J, Hajitou A, Marini FC 3rd, Wood CG, Wright KC, Fueyo J, Arap W, Pasqualini R.

Mol Ther. 2004 Feb;9(2):305-10.

37.

Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.

Devy L, de Groot FM, Blacher S, Hajitou A, Beusker PH, Scheeren HW, Foidart JM, Noël A.

FASEB J. 2004 Mar;18(3):565-7. Epub 2004 Jan 20.

PMID:
14734647
38.

The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells.

Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noël A.

FASEB J. 2002 Nov;16(13):1802-4. Epub 2002 Sep 19.

PMID:
12354694
39.

MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression.

Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A.

FASEB J. 2002 Apr;16(6):555-64.

PMID:
11919158
40.

Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.

Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, Yeh P, Perricaudet M, Chang Y, Soria C, Calberg-Bacq CM, Foidart JM, Noël A.

Cancer Res. 2001 Apr 15;61(8):3450-7.

41.

Progression in MCF-7 breast cancer cell tumorigenicity: compared effect of FGF-3 and FGF-4.

Hajitou A, Deroanne C, Noël A, Collette J, Nusgens B, Foidart JM, Calberg-Bacq CM.

Breast Cancer Res Treat. 2000 Mar;60(1):15-28.

PMID:
10845805
42.

Demonstration in vivo that stromelysin-3 functions through its proteolytic activity.

Noël A, Boulay A, Kebers F, Kannan R, Hajitou A, Calberg-Bacq CM, Basset P, Rio MC, Foidart JM.

Oncogene. 2000 Mar 16;19(12):1605-12.

43.

FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells.

Hajitou A, Baramova EN, Bajou K, Noë V, Bruyneel E, Mareel M, Collette J, Foidart JM, Calberg-Bacq CM.

Oncogene. 1998 Oct 22;17(16):2059-71.

44.

Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts.

Noël A, Hajitou A, L'Hoir C, Maquoi E, Baramova E, Lewalle JM, Remacle A, Kebers F, Brown P, Calberg-Bacq CM, Foidart JM.

Int J Cancer. 1998 Apr 13;76(2):267-73.

45.

Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression.

Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapière CM.

Cancer Res. 1997 Dec 15;57(24):5590-7.

46.

Fibroblast growth factor 3 is tumorigenic for mouse mammary cells orthotopically implanted in nude mice.

Hajitou A, Calberg-Bacq CM.

Int J Cancer. 1995 Nov 27;63(5):702-9.

PMID:
7591288

Supplemental Content

Loading ...
Support Center